A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

PHASE3CompletedINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

October 5, 2020

Study Completion Date

October 28, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (53)

15009

Heritage Valley Medical Group, Inc., Beaver

15236

Preferred Primary Care Physicians, Pittsburgh

15401

Preferred Primary Care Physicians, Uniontown

19056

Family Medical Associates, Levittown

30328

Agile Clinical Research Trials, Atlanta

30331

Sky Clinical Research Network, Atlanta

31217

Investigacion en Salud y Metabolismo S.C, Chihuahua City

33021

Encore Medical Research, LLC, Hollywood

33063

South Florida Wellness & Clinical Research Institute, Margate

33134

Clinical Research of South Florida, Coral Gables

33135

Suncoast Research Group, LLC, Miami

33470

Axcess Medical Research, Loxahatchee Groves

43213

Aventiv Research, Columbus

63005

Clinical Research Professionals, Chesterfield

63303

StudyMetrix Research, LLC, City of Saint Peters

64460

Hospital Universitario UANL, Monterrey

66465

Unidad Medica para la Salud Integral (UMSI), Monterrey

66606

Cotton O'Neil Clinic, Topeka

73069

Intend Research, Norman

75230

Dallas Diabetes Endocrine Center, Dallas

78229

Clinical Trials of Texas, Inc., San Antonio

78231

Consano Clinical Research, Shavano Park

89440

Centro de Estudios de Investigacion Metabolicos y Cardiovasc, Madero

90057

National Research Institute, Los Angeles

90255

National Research Institute, Huntington Park

91325

Valley Clinical Trials, Inc., Northridge

91402

National Research Institute, Panorama City

91763

Catalina Research Institute, LLC, Montclair

92701

Southern California Dermatology, Santa Ana

97330

The Corvallis Clinic P.C., Corvallis

98502

Capital Clinical Research Center, Olympia

99220

Rockwood Clinic Research Center, Spokane

380007

Dr. Jivraj Mehta Smarak Health Foundation, Ahmedabad

400058

BSES Municipal General Hsptl, Mumbai

401303

Vijay Vallabh Hospital, Virār

411001

Ruby Hall Clinic and Grant Medical Foundation, Pune

411057

Lifepoint Multispecialty Hsptl, Wakad

500003

Gandhi Hospital, Telangana

500072

Ramdevrao Hospital, Hyderabad

560054

M S Ramaiah Medical College Hospital, Bangalore

560 002

Bangalore Medical College and Research Institute, Bangalore

311-4153

Minamiakatsuka Clinic, Mito

247-0056

Takai Naika Clinic, Kamakura

242-0004

Tsuruma Kaneshiro Diabetes Clinic, Yamato

232-0064

Yokohama Minoru Clinic, Yokohama

569-1096

Takatsuki Red Cross Hospital, Takatsuki

101 0041

Meiwa Hospital, Chiyodaku

103-0027

Tokyo-Eki Center-building Clinic, Chuo-ku

103-0028

Tokyo Center Clinic, Chuo-ku

108 0075

IHL Shinagawa East One Medical Clinic, Minato-ku

143-0015

Sato Naika Clinic, Ōta-ku

00917

GCM Medical Group PSC, San Juan

00909

Clinical Research Puerto Rico, Inc., San Juan

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03954834 - A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Biotech Hunter | Biotech Hunter